tbuckley/cabot-search huggingface dataset:
THE MAJOR AND THE MINOR
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Figure
Journal: JAMA Pediatrics (2019)

Bobby Tan, BSc, MD; Judith Ju-Ming Wong, MBBCh, BAO, MRCPCH; Rehena Sultana, MSc; Janine Cynthia Jia Wen Koh, MBBS; Mark Jit, BSc, PhD, MPH; Yee Hui Mok, MBBS, MRCPCH; Jan Hau Lee, MBBS, MRCPCH, MCI
Surveillance for variant strains of HIV: subtype G and group O HIV-1
Authors: P. S. Sullivan
Journal: JAMA (1997)

<h3>To the Editor.</h3> —The state of Maryland, as part of the Centers for Disease Control and Prevention's national surveillance for human immunodeficiency virus (HIV) variants, collects blood from a sample of persons with acquired immunodeficiency syndrome (AIDS) for determination of viral subtype. Two patients infected with HIV-1 variants have been identified: the first identified HIV-1 subtype G infection in the United States, and the second identified HIV-1 group O infection in the United States.<sup>1</sup> Patient 1 was a woman in her mid 30s who was born in West Africa; HIV infection was diagnosed in the United States in the early 1990s. The patient was likely exposed to HIV by heterosexual contact with an HIV-infected person in Africa. She had severe immunosuppression and AIDS-defining opportunistic illnesses, including recurrent pneumonia, esophageal candidiasis, toxoplasma encephalitis, and disseminated cytomegalovirus disease. Death was attributed to HIV disease, pancytopenia, and cavernous sinus thrombosis. Plasma from
Gynecology. A Text-Book for Students and a Guide for Practitioners.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
INSANITY FROM IDLENESS IN PRISONS.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Only half of GPs in study knew that advance directives carry legal force in UK
Journal: BMJ (1999)

Objectives To investigate the effect of Chlamydia pneumoniae infection on future development of ischaemic heart disease and mortality.Design Prospective longitudinal study.Setting Caerphilly, South Wales.Subjects Plasma specimens were collected during 1979-83 from 1773 men aged 45-59 years.These were tested for IgG and IgA antibodies to C pneumoniae (TW183) by microimmunofluorescence. Outcome measures 13 year mortality and incident ischaemic heart disease events were ascertained from death certificates, hospital records, and electrocardiographic changes at follow up every 4 to 5 years.Results 642 men (36.2%) had IgG antibodies at a titre of >1 in 16, of whom 362 (20.4% of all men) also had detectable IgA antibodies.The prevalence of ischaemic heart disease (a history of past or current disease) at entry was similar at all IgG antibody titres but was positively related to IgA antibody titre.IgA antibody titre was positively correlated with plasma viscosity but not with other cardiovascular risk factors.Incidence of ischaemic heart disease was not associated with either IgG antibody titre or IgA antibody titre, but there were stronger and significant relations of IgA antibodies with all cause mortality and fatal ischaemic heart disease, which persisted after adjustment for conventional cardiovascular risk factors.The odds ratios associated with detectable IgA antibodies were 1.07 (95% confidence interval 0.75 to 1.53) for all incident ischaemic heart disease, 1.83 (1.17 to 2.85) for fatal ischaemic heart disease, and 1.50 (1.10 to 2.04) for all cause mortality.Conclusion This is the first prospective demonstration of an association between IgA antibodies to C pneumoniae, a putative marker of chronic infection, and subsequent risk of death from ischaemic heart disease.In contrast to earlier case-control studies, IgG antibodies were not associated with either prevalent or incident ischaemic heart disease.
Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS
Authors: Gareth P. Gregory, Michael Dickinson, Costas K. Yannakou, Jonathan Wong, Piers Blombery, Greg Corboy, Lev Kats, Tim M.E. Crozier, Beena Kumar, H. Miles Prince, Stephen S. Opat, Jake Shortt
Journal: HemaSphere (2019)
ESGE Newsletter
Journal: Endoscopy (2011)

After the resounding success of the first ESGE Quality in Endoscopy symposium on ERCP, which was held recently in Munich, planning for the next meeting in this series, ”colonoscopy and colonic neoplasms” is well underway. ESGE is joining forces with the European Society of Digestive Oncology (ESDO) for this event which will take place in Berlin in the spring of 2012.
Hyperthyroid crisis
Authors: S. R. Newmark
Journal: JAMA (1974)

THYROTOXIC storm is an overwhelming or uncompensated form of thyrotoxicosis.<sup>1</sup>Thyrotoxic storm appears commonly in two settings: After surgery, when the thyrotoxic patient has been prepared inadequately or the diagnosis of hyperthyroidism was not recognized preoperatively. In this instance, either "surgical stress" or direct manipulation of the gland results in acute release of thyroid hormone into the peripheral blood. More commonly, thyrotoxic storm arises during an intercurrent "stressful" medical illness, such as uncontrolled diabetes or ketoacidosis, trauma, or infection. Clinical manifestations are those of severe hypermetabolism. Fever is always present and ranges from 38 C (100 F) to 41 C (106 F). The skin has a fine texture and is warm and flushed. Sweating may be profuse. Pulse is rapid and atrial fibrillation may be present. Although the blood pressure is well maintained initially, shock may result ultimately. Pulmonary edema may be present, particularly if there is underlying cardiac
AMA/Glaxo Wellcome Leadership Award Winners, Part 1
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Reply:
Authors: Wilson Roa, Raul Urtasun, Glenn Bauman, J. Gregory Cairncross, Peter Forsyth
Journal: Journal of Clinical Oncology (2005)

We thank Drs Chamberlain, Recht, and Glantz for their interest in our work and thoughtful comments on our study. 1They raise the important issue of primary chemotherapy as an alternative treatment for elderly patients with glioblastoma multiforme (GBM).They correctly point out that, except for a few studies, elderly patients are usually excluded from prospective randomized studies.We agree that a randomized trial is the best way to compare an abbreviated course of radiotherapy to primary temozolomide (TMZ) in elderly GBM patients.One challenge in recruiting elderly patients onto randomized trials is concern about side effects, duration of therapy, and quality of life.Such a trial, therefore, will have to incorporate vigorous measurements of health-related quality of life, in addition to survival.Many important treatment questions remain in optimizing care for elderly patients with GBM.These include the role of aggressive surgery; primary chemotherapy versus radiotherapy; concurrent chemotherapy (eg, TMZ) plus radiotherapy, versus chemotherapy or radiotherapy alone; and sequential treatments.The prognosis for these patients is poor with our existing treatments.We need to explore new therapy options while we pursue properly designed randomized clinical trials.In the meantime, clinicians caring for older patients with GBM can use the data from us 1 and others 2,3 to decide on the most appropriate treatments for their patients.
Research questions: What questions need to be answered? What kind of answers does Endoscopy aim to publish?
Journal: Endoscopy (2016)

The aims of the European Society of Gastrointestinal Endoscopy (ESGE) include improving the quality of digestive endoscopy and promoting awareness, teaching, and research in gastrointestinal endoscopy and related fields. This is reflected in its current structure, with Committees dedicated to these goals. In recent years the ESGE Research Committee, chaired by Colin Rees (UK), has had a special interest in to defining the key unanswered questions within the field of gastrointestinal endoscopy [1], to foreground areas of high interest for researchers, scientific societies and, hopefully, funding organizations.
Vaccine policy likely to be reassessed in 1990s when polio-DTP combination becomes available
Authors: C. Marwick
Journal: JAMA (1988)

LIVE, as opposed to killed, virus is still the recommended poliomyelitis vaccine strategy—but probably not for much longer. The National Academy of Sciences— chartered Institute of Medicine, Washington, DC, is recommending that the present policy of immunization against poliomyelitis continue to emphasize the oral polio vaccine. The recommendation goes to the Public Health Service, which commissioned the study (<i>JAMA</i>1988; 259:1608-1609). At the same time, change is in the air. In the near future, circumstances are likely to develop that will make the new inactivated vaccine, which was licensed last November, more attractive. Within the next two to five years, the committee predicted that the new inactivated vaccine will be combined with diphtheria-tetanus-pertussis vaccine. When it is, the committee recommended considering a regimen that employs two or more doses of this agent as the primary immunogen followed by two doses of the oral vaccine, one at 18 months of age
CLINICAL NOTES ON CHOLERA
Authors: W. L. Lindsay
Journal: BMJ (1854)

ORGNLU WTOd pak in the had, and rEA'n-perfcly conscious until fr oelock, when a convulion fits her; but, asit oon pased of and she became composed, her husband thought abe was goe to sleep, and did not call me until the second atac came ou between six and seven.I then found the os utei bginng to dilate, being about the size of a shilling, and e had no return of convulsions until eight o'clock; * In descrbing the most illustrative pathologicil phenomena of cholera, where It Is not ot erwiso specialy meutioned, 1 am unuderstood to refer to cases fatal in the collapse step.
ACS/NIH Organ Transplant Registry
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mycosis fungoides: lack of helper lymphocytes in lymphocyte-monocyte interactions
Authors: D.A. Norris
Journal: British Journal of Dermatology (1978)

Journal Article Mycosis fungoides: lack of helper lymphocytes in lymphocyte‐monocyte interactions Get access D.A. Norris D.A. Norris Department of Dermatotogy, University of Colorado Medicat Centre Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 99, Issue s16, 1 December 1978, Page 16, https://doi.org/10.1111/j.1365-2133.1978.tb15210.x Published: 01 December 1978
Selected techniques in interventional radiology
Authors: R. I. White
Journal: JAMA (1981)

AN OUTGROWTH of diagnostic angiography was the realization that an intravascular catheter could be used for much more than delineating arterial and venous anatomy. Viewed in its simplest form, interventional radiology is considered any selective catheter technique adopted for treatment. Such techniques include intravascular infusion of vasodilators or vasoconstrictors or mechanical dilatation or occlusion of a vascular bed. Chemotherapeutic agents can be infused for palliation of metastatic neoplasms, and modified angiographic catheters, needles, and guide wires are used for drainage procedures in the biliary and urinary tract. The following material highlights some of these advances in interventional radiology and also describes developments that are likely to occur in the next decade. <h3>Percutaneous Transluminal Angioplasty (PTA)</h3> Just 16 years ago, in 1964, Dotter and Jadkins<sup>1</sup>described the technique employing telescoping catheters to recanalize atherosclerotic stenoses of the femoral arteries. The technique was preserved and further developed by the pioneering efforts
BAL
Authors: Raymond V. Randall, Albert O. Seeler
Journal: New England Journal of Medicine (1948)

THE discovery of BAL (2,3–dimercaptopropanol) by Peters and his co-workers1 in England was the result of an intensive search for a substance that would be effective in treating severe burns caused by contact with certain arsenical war gases such as lewisite. The name BAL is an abbreviation of "British Anti-Lewisite," a term applied to this substance after it had proved to be effective against lewisite. It was soon found that this compound was of value not only in treating the local effects of arsenical war gases but also in combating the systemic disturbances following their absorption. Moreover, BAL proved to . . .
RUSSIAN ROULETTE
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Errors in Key Points and Conclusions and in Editorial
Authors: David Li, Arash Mostaghimi
Journal: JAMA Dermatology (2019)

out of in vivo bioequivalence testing in 5 cases, while recommending comparative physicochemical characterization in the final case. 5 Given these requirements, it is likely that existing FDA requirements may dissuade manufacturers from entering these restricted markets.Although we are in complete support of efforts to streamline drug approval, variations between topical medications may render in vitro evaluation unsuitable for some medications.For example, differences in vehicle can potentially alter the performance of a generic formulation in a manner that may not be captured by in vitro studies alone. 3,6Additionally, the intrinsic properties of select topical drugs may interfere with the reliability of in vitro testing.One recent study illustrated the difficulty of standardizing the in vitro release test for betamethasone valerate owing to its high solubility in hydrophobic barriers. 3espite these differences, the FDA's rationale for mandating in vivo studies for some drugs while allowing the in vitro option in others is not fully elucidated.Development and validation of criteria to identify topical drugs that can be granted an in vitro testing option may improve throughput of new medications without compromising trust in the equivalent performance of generic medications entering the market.While these criteria are being developed, short-term improvements in market competition may be realized by subsidizing a portion of costs associated with clinical trials for generic drug manufacturers entering restricted markets.Although we agree that the current recommendations for bioequivalence studies may discourage drug manufacturers, a rapid transition toward in vitro testing may compromise the integrity of topical dermatology generic drugs reaching the market.Until researchers and regulators can decide on a transparent and standardized framework for the design of bioequivalence studies, barriers to entry will continue to limit the impact of competition on keeping topical drug prices in check.
Pathology
Authors: Lester S. King
Journal: JAMA (1966)

Anderson's<i>Pathology</i>, popular since its first appearance in 1948, represents one of the standard American texts. The present edition now appears in two volumes, with considerable up-dating but the same basic format. Whereas the fourth edition had 35 contributors, the present one has 39. The number of pages is but slightly increased, the number of illustrations actually reduced, and the two volumes together have just about the same thickness as the single volume of the fourth edition. There is no need to discuss the individual features in a book so well known, so widely accepted, and so deserving of its excellent reputation. But a few words may be in order regarding the goals and intent. In the preface to the first edition Anderson indicated a dual audience —he hoped the book would be "both a foundation and a useful tool" for those who deal with disease. This schema has remained
Reply
Authors: T K Daneshmend, G. Parker, C J C Roberts
Journal: Gut (1984)

agents.We are pleased to be able to give preliminary results of the effect of edrophonium administered during coronary angiography.The results of this study will be published,1 indicating that edrophonium was not associated with spasm or other abnormality of the coronary arteries.There- fore we stand by our suggestion that edrophonium is a safer provocative agent than ergometrine, which is itself used to provoke coronary artery spasm.